Text Size

Post-marketing surveillance of Levofloxacin 0.5% ophthalmic solution for external ocular infections

Kanda Y., Kayama T., Okamoto S., Hashimoto M., Ishida C., Yanai T., Fukumoto M., Kunihiro E.

  • 2012
  • Drugs in R and D
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Post-Marketing Surveillance Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Drug Safety Information Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Safety Vigilance Group, Santen Pharmaceutical Co., Ltd., 3-9-19 Shimo-Shinjo, Osaka 533-8651, Japan

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022